Literature DB >> 11070169

Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite.

S Reich-Zeliger1, Y Zhao, R Krauthgamer, E Bachar-Lustig, Y Reisner.   

Abstract

Several bone marrow cells and lymphocyte subpopulations, known as "veto cells," were shown to induce transplantation tolerance across major histocompatibility antigens. Recently, it has been suggested that anti-third party CTLs depleted of alloreactivity are endowed with marked veto activity and therefore might potentially facilitate bone marrow allografting without graft versus host disease (GVHD). The veto mechanism is still obscure. While early studies emphasized the role of CD8-mediated apoptosis, more recent evidence indicates a role for Fas-FasL. In the present study we show, by using blocking anti-CD8 antibody, by generating CTLs from FasL or perforin mutated mice, and by gene transfer of FasL, that the veto activity of anti-third party CD8+ CTLs is dependent upon the simultaneous expression of both CD8 and FasL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070169     DOI: 10.1016/s1074-7613(00)00050-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  21 in total

Review 1.  Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation.

Authors:  Catherine T Jordan; John D Roback
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  CTLs respond with activation and granule secretion when serving as targets for T-cell recognition.

Authors:  Oren Milstein; David Hagin; Assaf Lask; Shlomit Reich-Zeliger; Elias Shezen; Eran Ophir; Yaki Eidelstein; Ran Afik; Yaron E Antebi; Michael L Dustin; Yair Reisner
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

3.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

4.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Authors:  Eran Ophir; Noga Or-Geva; Irina Gurevich; Orna Tal; Yaki Eidelstein; Elias Shezen; Raanan Margalit; Assaf Lask; Guy Shakhar; David Hagin; Esther Bachar-Lustig; Shlomit Reich-Zeliger; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

Review 6.  New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Authors:  Mark L Tykocinski; Aoshuang Chen; Jui-Han Huang; Matthew C Weber; Guoxing Zheng
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 7.  Immune tolerance and transplantation.

Authors:  Onder Alpdogan; Marcel R M van den Brink
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

8.  Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.

Authors:  Jacopo Mariotti; Jason Foley; Kaitlyn Ryan; Nicole Buxhoeveden; Veena Kapoor; Shoba Amarnath; Daniel H Fowler
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

9.  Hematopoietic stem cell transplantation across major genetic barriers.

Authors:  Yair Reisner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling.

Authors:  Gudrun Strauss; Jonathan A Lindquist; Nathalie Arhel; Edward Felder; Sabine Karl; Tobias L Haas; Simone Fulda; Henning Walczak; Frank Kirchhoff; Klaus-Michael Debatin
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.